A single center retrospective cohort study assessing the short term tolerability of Ocrelizumab in patients with a predominantly relapsing remitting Multiple Sclerosis and a progressive MS disease at real world
Latest Information Update: 01 Jun 2021
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 01 Jun 2021 New trial record